Local versus general anesthesia transperineal prostate biopsy: Tolerability, cancer detection, and complications.
cancer detection
complications
local anaesthesia
prostate cancer
tolerability
transperineal biopsy
Journal
BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
18
05
2021
revised:
05
07
2021
accepted:
09
08
2021
entrez:
27
4
2022
pubmed:
28
4
2022
medline:
28
4
2022
Statut:
epublish
Résumé
To compare data on transperineal template biopsy (TPTB) under general anesthesia (GA) compared with local anesthesia (LA) procedures using the PrecisionPoint™ Transperineal Access System (PPTAS) in relation to tolerability, cancer detection rate, complications, and cost. A prospective pilot cohort study of patients undergoing transperineal biopsy was performed. Patients were excluded if they had concurrent flexible cystoscopy or language barriers. Patients had a choice of GA or LA. A prospective questionnaire on Days 0, 1, 7, and 30 was applied. The primary outcome was patient tolerability. Secondary outcomes were cancer detection rate, complication rate, and theater utilization. This study included 80 patients (40 GA TPTB and 40 LA PPTAS). Baseline characteristics including age, prostate-specific antigen (PSA), digital rectal examination (DRE), findings, and prostate volume were comparable between the groups ( This study demonstrates that transperineal biopsy is safely performed under LA with no difference between the cohorts in relation cancer detection or AUR. LA biopsy also consumed less theater and recovery resources. A further larger prospective randomized controlled trial is required to confirm the findings of this study.
Identifiants
pubmed: 35474705
doi: 10.1002/bco2.106
pii: BCO2106
pmc: PMC8988812
doi:
Types de publication
Journal Article
Langues
eng
Pagination
428-435Informations de copyright
© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Déclaration de conflit d'intérêts
We confirm that this paper has not been published or submitted for publication elsewhere and that all authors have contributed significantly and are all in agreement with the content of the manuscript. The following apply to all listed authors: All support for the present manuscript (e.g., funding, provision of study materials, medical writing, and article processing charges): noneGrants or contracts from any entity: noneRoyalties of licenses: noneConsulting fees: nonePayment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events: nonePayment for expert testimony: noneSupport for attending meetings and/or travel: nonePatents planned, issued, or pending: noneParticipation on a data safety monitoring board or advisory board: noneLeadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: noneStock or stock options: noneReceipt of equipment, materials, drugs, medical writing, gifts, or other services: noneOther financial or nonfinancial interests: none
Références
BMC Urol. 2018 May 30;18(1):51
pubmed: 29843694
J Antimicrob Chemother. 2011 Mar;66(3):664-9
pubmed: 21172788
World J Urol. 2017 Nov;35(11):1681-1688
pubmed: 28470334
Urology. 2018 May;115:8-13
pubmed: 29409845
BJUI Compass. 2021 Sep 10;2(6):428-435
pubmed: 35474705
BJU Int. 2020 Feb;125(2):244-252
pubmed: 30431694
BJU Int. 2014 Jul;114(1):32-7
pubmed: 24053629
BJU Int. 2015 Oct;116 Suppl 3:49-53
pubmed: 26176815
Sci Rep. 2015 Nov 03;5:16089
pubmed: 26526558
J Urol. 2021 Oct;206(4):894-902
pubmed: 34100650
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):62-65
pubmed: 31932659
BJU Int. 2014 Sep;114(3):384-8
pubmed: 24612341
Rev Urol. 2018;20(1):19-25
pubmed: 29942197
J Urol. 2013 Jan;189(1 Suppl):S12-7; discussion S17-8
pubmed: 23234616
BJU Int. 2020 Jul;126(1):133-141
pubmed: 32232966
J Clin Urol. 2018 May;11(3):192-199
pubmed: 29881622
Contemp Clin Trials. 2015 May;42:26-40
pubmed: 25749312
Int J Urol. 2009 Apr;16(4):420-3
pubmed: 19416405
J Urol. 2013 Mar;189(3):860-6
pubmed: 23063807
BJU Int. 2013 Sep;112(5):585-93
pubmed: 23551500
BJU Int. 2012 Jul;110(2 Pt 2):E69-75
pubmed: 22093091
BJU Int. 2015 Oct;116(4):568-76
pubmed: 25560926
World J Urol. 2020 Aug;38(8):1943-1949
pubmed: 31679065
BJU Int. 2020 Feb;125(2):260-269
pubmed: 31306539
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):311-317
pubmed: 28485391